Marker Therapeutics, Inc. MRKR

MRKR Company Overview

Marker Therapeutics, Inc. is a clinical-stage immuno-oncology biotechnology company focused on the development of T cell-based therapies for the treatment of hematological malignancies and solid tumors. The company operates within the biotechnology and cellular immunotherapy industries, with its primary focus centered on engineered and non-engineered multi-tumor associated antigen (multiTAA)-specific T cell therapies. Marker’s core technology platform is designed to target multiple tumor antigens simultaneously, with the goal of reducing tumor escape mechanisms that can occur with single-target therapies.

The company’s primary revenue sources have historically consisted of collaboration agreements, grant funding, and financing activities, as it remains a development-stage enterprise without commercialized products. Marker has concentrated much of its clinical development on acute myeloid leukemia (AML) and lymphoma indications. The company evolved from research conducted at Baylor College of Medicine and underwent strategic restructuring following the merger of TapImmune Inc. and Marker Therapeutics in 2018. Marker’s positioning in the cell therapy market is tied to its use of non-genetically modified T cells, which may offer manufacturing and safety advantages relative to certain genetically engineered CAR-T approaches.